Artículos relevantes

    • Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP. Rheumatology (Oxford). 2010 Feb;49(2):271-80. Epub 2009 May 15. (ver aqui)

     

    •  Predictors of major infections in systemic lupus erythematosus . Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Arthritis Res Ther. 2009;11(4):R109. Epub 2009 Jul 15. (ver aqui)

     

    • Antiphospholipid antibodies and renal involvement Gigante A, Gasperini ML, Cianci R, Barbano B, Giannakakis K, Di Donato D, Fuiano G, Amoroso A. Am J Nephrol. 2009;30(5):405-12. Epub 2009 Aug 28. (ver aqui)

     

    • Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis. Visser K, et al. Ann Rheum Dis 2009. (ver aqui)

     

    • Antiphospholipid syndrome. Espinosa G, Cervera R. Art Res Ther 2008. (ver aqui)

     

    • Primary Sjögren Syndrome in Spain. Clinical and immunological expression in 1010 patients. Ramos-Casals M, et al. Medicine (Baltimore) 2008. (ver aqui)

     

    • A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Ruiz-Irastorza G, et al. Art Rheum 2007. (ver aqui)